{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:26:49Z","timestamp":1792578409959,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11523-025-01146-4","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T05:47:49Z","timestamp":1747806469000},"page":"445-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation"],"prefix":"10.1007","volume":"20","author":[{"given":"Fred","family":"Saad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel W.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"issue":"3","key":"1146_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1146_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clgc.2016.08.018","volume":"15","author":"DM Moreira","year":"2017","unstructured":"Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, et al. Predicting time from metastasis to overall survival in castration-resistant prostate cancer: results from SEARCH. Clin Genitourin Cancer. 2017;15(1):60-6.e2.","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"1146_CR3","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","volume":"38","author":"ND Shore","year":"2021","unstructured":"Shore ND, Laliberte F, Ionescu-Ittu R, Yang L, Mahendran M, Lejeune D, et al. Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors. Adv Ther. 2021;38(8):4520\u201340.","journal-title":"Adv Ther"},{"issue":"16 Suppl","key":"1146_CR4","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.1200\/JCO.2024.42.16_suppl.5054","volume":"42","author":"F Kariburyo-Yay","year":"2024","unstructured":"Kariburyo-Yay F, George DJ, Aggarwal H, Tepsick JG, Yu R, Li W, et al. Real-world baseline treatment patterns and overall survival (rwOS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in the United States. J Clin Oncol. 2024;42(16 Suppl):5054.","journal-title":"J Clin Oncol"},{"issue":"22","key":"1146_CR5","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091\u2013102.","journal-title":"N Engl J Med"},{"key":"1146_CR6","doi-asserted-by":"publisher","first-page":"v328","DOI":"10.1093\/annonc\/mdz248.004","volume":"30","author":"JS de Bono","year":"2019","unstructured":"de Bono JS, Fizazi K, Saad F, Shore N, Sandhu SK, Mehra N, et al. Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >\u00a04000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study. Ann Oncol. 2019;30:v328\u20139.","journal-title":"Ann Oncol"},{"issue":"4","key":"1146_CR7","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41391-023-00764-1","volume":"27","author":"IM Shui","year":"2024","unstructured":"Shui IM, Burcu M, Shao C, Chen C, Liao CY, Jiang S, et al. Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases. Prostate Cancer Prostatic Dis. 2024;27(4):728\u201335.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"1146_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443\u201353.","journal-title":"N Engl J Med"},{"issue":"9","key":"1146_CR9","doi-asserted-by":"publisher","first-page":"EVIDoa200043","DOI":"10.1056\/EVIDoa2200043","volume":"1","author":"NW Clarke","year":"2022","unstructured":"Clarke NW, Armstrong AA, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1(9):EVIDoa200043.","journal-title":"NEJM Evid."},{"issue":"6","key":"1146_CR10","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.18.00358","volume":"37","author":"E Castro","year":"2019","unstructured":"Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37(6):490\u2013503.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1146_CR11","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","volume":"35","author":"D Olmos","year":"2024","unstructured":"Olmos D, Lorente D, Alameda D, Cattrini C, Romero-Laorden N, Lozano R, et al. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. Ann Oncol. 2024;35(5):458\u201372.","journal-title":"Ann Oncol"},{"key":"1146_CR12","unstructured":"Referenced with permission from the NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for prostate cancer V.3.2024. \u00a9 National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed 25 April, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"6","key":"1146_CR13","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol. 2023;209(6):1082\u201390.","journal-title":"J Urol"},{"key":"1146_CR14","unstructured":"Cornford P, Tilki D, van den Bergh RCN, Briers E, Eberli D, De Meerleer G, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. 2024. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2024.pdf. Accessed Oct 2024."},{"issue":"10","key":"1146_CR15","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1158\/2767-9764.CRC-22-0119","volume":"2","author":"K Jamal","year":"2022","unstructured":"Jamal K, Galbiati A, Armenia J, Illuzzi G, Hall J, Bentouati S, et al. Drug\u2013gene interaction screens coupled to tumor data analyses identify the most clinically relevant cancer vulnerabilities driving sensitivity to PARP inhibition. Cancer Res Commun. 2022;2(10):1244\u201354.","journal-title":"Cancer Res Commun."},{"issue":"10","key":"1146_CR16","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18(10):610\u201321.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6330","key":"1146_CR17","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152\u20138.","journal-title":"Science"},{"issue":"4","key":"1146_CR18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","volume":"60","author":"MJ O'Connor","year":"2015","unstructured":"O\u2019Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547\u201360.","journal-title":"Mol Cell"},{"issue":"1","key":"1146_CR19","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","volume":"8","author":"M Asim","year":"2017","unstructured":"Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;8(1):374.","journal-title":"Nat Commun"},{"issue":"12","key":"1146_CR20","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","volume":"2","author":"MJ Schiewer","year":"2012","unstructured":"Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012;2(12):1134\u201349.","journal-title":"Cancer Discov"},{"issue":"480","key":"1146_CR21","doi-asserted-by":"publisher","first-page":"eaam7479","DOI":"10.1126\/scisignal.aam7479","volume":"10","author":"L Li","year":"2017","unstructured":"Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, et al. Androgen receptor inhibitor\u2013induced \u201cBRCAness\u201d and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017;10(480):eaam7479.","journal-title":"Sci Signal."},{"issue":"26","key":"1146_CR22","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495\u2013505.","journal-title":"N Engl J Med"},{"issue":"4","key":"1146_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317\u201327.","journal-title":"N Engl J Med"},{"issue":"3","key":"1146_CR24","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol. 2015;33(3):244\u201350.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1146_CR25","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, Phase 3 trial. Lancet Oncol. 2017;18(9):1274\u201384.","journal-title":"Lancet Oncol"},{"issue":"15","key":"1146_CR26","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382\u201392.","journal-title":"N Engl J Med"},{"issue":"8","key":"1146_CR27","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852\u201361.","journal-title":"Lancet Oncol"},{"issue":"25","key":"1146_CR28","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med"},{"issue":"6","key":"1146_CR29","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333.","journal-title":"N Engl J Med"},{"issue":"25","key":"1146_CR30","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394\u2013405.","journal-title":"N Engl J Med"},{"issue":"11","key":"1146_CR31","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","volume":"26","author":"W Abida","year":"2020","unstructured":"Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the Phase II TRITON2 study. Clin Cancer Res. 2020;26(11):2487\u201396.","journal-title":"Clin Cancer Res"},{"issue":"10398","key":"1146_CR32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402(10398):291\u2013303.","journal-title":"Lancet"},{"issue":"18","key":"1146_CR33","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","volume":"41","author":"KN Chi","year":"2023","unstructured":"Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol. 2023;41(18):3339\u201351.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1146_CR34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","volume":"30","author":"K Fizazi","year":"2024","unstructured":"Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, et al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2024;30(1):257\u201364.","journal-title":"Nat Med"},{"issue":"10","key":"1146_CR35","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(10):1067\u201396.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"1146_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.trecan.2019.11.006","volume":"6","author":"D Mandelker","year":"2020","unstructured":"Mandelker D, Ceyhan-Birsoy O. Evolving significance of tumor-normal sequencing in cancer care. Trends Cancer. 2020;6(1):31\u20139.","journal-title":"Trends Cancer."},{"issue":"11","key":"1146_CR37","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.3390\/ijms22115522","volume":"22","author":"A Cimadamore","year":"2021","unstructured":"Cimadamore A, Cheng L, Massari F, Santoni M, Pepi L, Franzese C, et al. Circulating tumor DNA testing for homology recombination repair genes in prostate cancer: from the lab to the clinic. Int J Mol Sci. 2021;22(11):5522.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1146_CR38","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41571-022-00660-y","volume":"19","author":"A Tivey","year":"2022","unstructured":"Tivey A, Church M, Rothwell D, Dive C, Cook N. Circulating tumour DNA\u2014looking beyond the blood. Nat Rev Clin Oncol. 2022;19(9):600\u201312.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1146_CR39","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","volume":"15","author":"NM Fonseca","year":"2024","unstructured":"Fonseca NM, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha AJ, et al. Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat Commun. 2024;15(1):1828.","journal-title":"Nat Commun"},{"issue":"6","key":"1146_CR40","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.euo.2024.05.003","volume":"7","author":"M Baboudjian","year":"2024","unstructured":"Baboudjian M, Peyrottes A, Dariane C, Fromont G, Denis JA, Fiard G, et al. Circulating biomarkers predictive of treatment response in patients with hormone-sensitive or castration-resistant metastatic prostate cancer: a systematic review. Eur Urol Oncol. 2024;7(6):1228\u201345.","journal-title":"Eur Urol Oncol."},{"issue":"4","key":"1146_CR41","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3390\/ma12040654","volume":"12","author":"J Cheng","year":"2019","unstructured":"Cheng J, Nonaka T, Wong DTW. Salivary exosomes as nanocarriers for cancer biomarker delivery. Materials (Basel). 2019;12(4):654.","journal-title":"Materials (Basel)."},{"issue":"3","key":"1146_CR42","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41416-020-01114-x","volume":"124","author":"R Lozano","year":"2021","unstructured":"Lozano R, Castro E, Aragon IM, Cendon Y, Cattrini C, Lopez-Casas PP, et al. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. Br J Cancer. 2021;124(3):552\u201363.","journal-title":"Br J Cancer"},{"issue":"5","key":"1146_CR43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.23.00339","volume":"42","author":"J Mateo","year":"2024","unstructured":"Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound trial. J Clin Oncol. 2024;42(5):571\u201383.","journal-title":"J Clin Oncol"},{"issue":"34","key":"1146_CR44","first-page":"S993","volume":"2023","author":"SK Sandhu","year":"1835","unstructured":"Sandhu SK, Gotto G, Vera-Badillo FE, Byun SS, Cutuli HJ, Gomes AJPDS, et al. A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC). Ann Oncol. 1835P;2023(34):S993.","journal-title":"Ann Oncol"},{"issue":"8","key":"1146_CR45","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","volume":"28","author":"M Hussain","year":"2022","unstructured":"Hussain M, Corcoran C, Sibilla C, Fizazi K, Saad F, Shore N, et al. Tumor genomic testing for >4,000 men with metastatic castration-resistant prostate cancer in the Phase III trial PROfound (olaparib). Clin Cancer Res. 2022;28(8):1518\u201330.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1146_CR46","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1158\/1078-0432.CCR-22-0931","volume":"29","author":"KN Chi","year":"2023","unstructured":"Chi KN, Barnicle A, Sibilla C, Lai Z, Corcoran C, Barrett JC, et al. Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound. Clin Cancer Res. 2023;29(1):81\u201391.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1146_CR47","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/jamaoncol.2020.5161","volume":"7","author":"K Jensen","year":"2021","unstructured":"Jensen K, Konnick EQ, Schweizer MT, Sokolova AO, Grivas P, Cheng HH, et al. Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference. JAMA Oncol. 2021;7(1):107\u201310.","journal-title":"JAMA Oncol"},{"issue":"Suppl 7","key":"1146_CR48","doi-asserted-by":"publisher","first-page":"S1168","DOI":"10.1016\/j.annonc.2022.07.1502","volume":"33","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Saad F, Thiery-Vuillemin A, Oya M, Shore ND, Mehra N, et al. Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the Phase III PROpel trial. Ann Oncol. 2022;33(Suppl 7):S1168 (abst 370P).","journal-title":"Ann Oncol"},{"issue":"22","key":"1146_CR49","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.2217\/fon-2021-0153","volume":"17","author":"N Shore","year":"2021","unstructured":"Shore N, Ionescu-Ittu R, Yang L, Laliberte F, Mahendran M, Lejeune D, et al. Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. Future Oncol. 2021;17(22):2907\u201321.","journal-title":"Future Oncol"},{"issue":"8","key":"1146_CR50","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2217\/fon-2021-1113","volume":"18","author":"A Leith","year":"2022","unstructured":"Leith A, Ribbands A, Kim J, Last M, Barlow S, Yang L, et al. Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan. Future Oncol. 2022;18(8):937\u201351.","journal-title":"Future Oncol"},{"issue":"3","key":"1146_CR51","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41391-021-00469-3","volume":"25","author":"N Weise","year":"2022","unstructured":"Weise N, Shaya J, Javier-Desloges J, Cheng HH, Madlensky L, McKay RR. Disparities in germline testing among racial minorities with prostate cancer. Prostate Cancer Prostatic Dis. 2022;25(3):403\u201310.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5_suppl","key":"1146_CR52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1200\/JCO.2025.43.5_suppl.85","volume":"43","author":"ND Shore","year":"2025","unstructured":"Shore ND, Vasudevan A, Li J, Qureshi H, Sathyan P, Aton L, et al. Real-world clinical practice gaps in timely homologous recombination repair gene mutation (HRRm) testing and poly (ADP-ribose) polymerase inhibitor (PARPi) treatment of patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2025;43(5_suppl):85.","journal-title":"J Clin Oncol"},{"issue":"24","key":"1146_CR53","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"M Hussain","year":"2020","unstructured":"Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383(24):2345\u201357.","journal-title":"N Engl J Med"},{"key":"1146_CR54","unstructured":"AstraZeneca. LYNPARZA\u00ae (olaparib) prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/208558s023lbl.pdf. Accessed Oct 2024."},{"issue":"12","key":"1146_CR55","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","volume":"20","author":"DJ Khalaf","year":"2019","unstructured":"Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019;20(12):1730\u20139.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1146_CR56","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1093\/annonc\/mdt138","volume":"24","author":"KL Noonan","year":"2013","unstructured":"Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24(7):1802\u20137.","journal-title":"Ann Oncol"},{"key":"1146_CR57","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejca.2022.04.016","volume":"170","author":"G Roubaud","year":"2022","unstructured":"Roubaud G, Ozguroglu M, Penel N, Matsubara N, Mehra N, Kolinsky MP, et al. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. Eur J Cancer. 2022;170:73\u201384.","journal-title":"Eur J Cancer"},{"issue":"10","key":"1146_CR58","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, Phase 3 trial. Lancet Oncol. 2023;24(10):1094\u2013108.","journal-title":"Lancet Oncol"},{"key":"1146_CR59","unstructured":"AstraZeneca. Lynparza\u00ae(olaparib) summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lynparza-epar-product-information_en.pdf. Accessed Mar 2025."},{"issue":"23","key":"1146_CR60","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 2019;116(23):11428\u201336.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1146_CR61","unstructured":"AstraZeneca. Lynparza\u00ae (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer. 2023. https:\/\/www.fda.gov\/media\/167485\/download. Accessed Mar 2024."},{"issue":"Suppl 7","key":"1146_CR62","first-page":"S616","volume":"33","author":"F Saad","year":"2022","unstructured":"Saad F, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Procopio G, et al. Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol. 2022;33(Suppl 7):S616\u201352 (abst 1357O).","journal-title":"Ann Oncol"},{"issue":"1","key":"1146_CR63","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","volume":"21","author":"J Mateo","year":"2020","unstructured":"Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):162\u201374.","journal-title":"Lancet Oncol"},{"issue":"19","key":"1146_CR64","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1158\/1078-0432.CCR-24-1402","volume":"30","author":"M Hussain","year":"2024","unstructured":"Hussain M, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller CJ, et al. Abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer with DNA repair defects (BRCAAway). Clin Cancer Res. 2024;30(19):4318\u201328.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1146_CR65","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or physician\u2019s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719\u201332.","journal-title":"N Engl J Med"},{"issue":"7","key":"1146_CR66","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamaoncol.2024.0851","volume":"10","author":"PC Barata","year":"2024","unstructured":"Barata PC, Assayag J, Li B, Siu G, Niyazov A. Genetic testing in men with metastatic castration-resistant prostate cancer. JAMA Oncol. 2024;10(7):975\u20137.","journal-title":"JAMA Oncol"},{"key":"1146_CR67","unstructured":"FDA approves Novartis radioligand therapy Pluvicto for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer. News release. [press release]. Published online and accessed April 2, 2025. https:\/\/www.novartis.com\/news\/media-releases\/fda-approves-novartis-radioligand-therapy-pluvicto-earlier-use-chemotherapy-psma-positive-metastatic-castration-resistant-prostate-cancer2025."},{"issue":"6","key":"1146_CR68","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.euo.2024.03.006","volume":"7","author":"F Saad","year":"2024","unstructured":"Saad F, Armstrong AJ, Oya M, Vianna K, Ozguroglu M, Gedye C, et al. Tolerability of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: Further results from the Phase 3 PROpel trial. Eur Urol Oncol. 2024;7(6):1394\u2013402.","journal-title":"Eur Urol Oncol."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01146-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01146-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01146-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T13:02:43Z","timestamp":1748264563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01146-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1146"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01146-4","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"18 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial support was provided by AstraZeneca and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, who are codeveloping olaparib.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Fred Saad has received consultancy and advisory fees from AbbVie, Advanced Accelerator Applications, Astellas Pharma, AstraZeneca\/MedImmune, Bayer, Janssen Oncology, Knight Therapeutics, Myovant Sciences, Novartis, Pfizer, and Sanofi; honoraria from AbbVie, Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen Oncology, Knight Therapeutics, Merck, Myovant Sciences, Novartis, Pfizer, and Sanofi; and institutional research funding from Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen Oncology, Merck, Novartis, Pfizer, and Sanofi. Andrew J. Armstrong has received consultancy or advisory fees from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Clovis Oncology, Dendreon, Exelixis, FORMA Therapeutics, GoodRX, Janssen, Merck, Myovant Sciences, Novartis, and Pfizer; travel and accommodation expenses from Astellas; and institutional research funding from Amgen, Astellas Pharma, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Constellation Pharmaceuticals, Dendreon, FORMA Therapeutics, Janssen Oncology, Gilead Sciences, Merck, Novartis, Pfizer, and Roche\/Genentech and holds institutional patents, royalties, and other intellectual property for circulating tumor cell novel capture technology. Neal Shore has acted in a consulting or advisory role for AbbVie, Accord, Alessa Therapeutics, Amgen, Antev, Asieris, Astellas, AstraZeneca, Aura Biosciences, Bayer, Bioprotect, Bristol Myers Squibb, Boston Scientific, CGOncology, Clarity, Dendreon, Exact Imaging, Ferring, Fize Medical, Foundation Medicine, Invitae, Janssen, Lantheus, Lilly, Dxhealth, Merck, Minomic, Myriad, Novartis, Pfizer, Photocure, Promaxo, Protara, Sanofi Genzyme, Telix, Tolmar, and Urogen; and in a leadership or fiduciary role for Alessa Photocure and Tuteix. Neal Shore is an editorial board member of Targeted Oncology and as such was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions. Daniel J. George has received grants from Calithera, Convergence, and Corvus; grants and personal fees from Astellas, Bristol Myers Squibb, Johnson and Johnson Pharmaceuticals, Merck Sharp & Dohme, Novartis, and Pfizer; personal fees from AstraZeneca, Axess Oncology, Capio Bioscience, Flatiron, Michael J Hennessey Associates, Millennium Medical Publishing, Myovant Sciences Inc, NCI Genitourinary, Nektar Therapeutics, Physician Education Resource, UroGPO, Vizuri Health Sciences, Platform Q, Propella Therapeutics, RevHealth, Seattle Genetics, WebMD, and Xcures; grants, personal fees, and non-financial support from Bayer Healthcare Pharmaceuticals, and Exelixis Inc; personal fees and non-financial support from UroToday; and other support from the American Association for Cancer Research, all outside of the submitted work. Mototsugu Oya has received consultancy or advisory fees from Bayer; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb Japan, Chugai, Janssen, MSD, Novartis, Ono Pharmaceuticals, Pfizer, Sanofi, and Takeda and research funding from Astellas Pharma, Novartis, and Pfizer. Mikio Sugimoto has received honoraria from Astellas, AstraZeneca, Janssen Pharmaceuticals, and Takeda; research funding from Astellas, AstraZeneca, Bristol Myers Squibb, Janssen, MSD, and Pfizer; and travel and accommodation expenses from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen, and MSD. Rana R. McKay has received institutional grant\/research support from AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Oncternal, and Tempus; consultancy fees from Arcus, Ambrx, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Caris, Dendreon, Eisai, Exelixis, Johnson & Johnson, Lilly, Merck, Myovant, NeoMorph, Novartis, Pfizer, Sanofi, SeaGen, Sorrento Therapeutics, Telix, and Tempus. Maha Hussain has received honoraria from AstraZeneca, Bayer, Convergent, Novartis, and Tango; has served on advisory boards and received honoraria for the following invited educational events\/lectures\/manuscripts: PROST8 Consensus Conference Steering Committee member and session chair (honorarium received from MJH, RTP Lecture, AACR Satellite Symposium Lecture, Academic CME and travel expenses); South Africa Oncology Society lecture (honorarium received from AstraZeneca); Bayer APEX meeting (travel\/accommodation, honorarium); 2nd International Genitourinary Cancer Conference Prostate Cancer Educational program (honorarium received from AstraZeneca); PER\/NYGU \u2013 co-chair\/speaker, RTP, Prostate Cancer Diagnostic Medical Education (Virtual) program (honorarium from AstraZeneca). Maha Hussain has also had clinical trials funding contracts with Arvinas, AstraZeneca, Bayer, and Northwestern University. Noel W. Clarke has received institutional consultancy or advisory fees from Astellas Pharma, Bayer, Ferring, Janssen-Cilag, and Sanofi; speaker bureau fees from Astellas Pharma, AstraZeneca, Bayer, Janssen-Cilag, Pfizer, and Sanofi; and travel and accommodation expenses associated with lectures and advisory board meetings from Astellas Pharma, AstraZeneca, Bayer, Ferring, Ipsen, Janssen-Cilag, and Sanofi.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No new data were generated or analyzed in support of this research.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the concept and development of this review article, including drafting and critical revision of the manuscript. All authors have approved the submitted version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}